The formation of the HU3DINKS Consortium sees bioprinting companies coming together.

Share this story

A groundbreaking international consortium called HU3DINKS has emerged with a revolutionary mission: to develop advanced bioinks for 3D bioprinting using human tissue. The consortium, supported by IraSME, FFG, and VLAIO, aims to replace synthetic and animal-derived bioinks and take the lead in the bioprinting revolution.

Currently, many bioinks used in bioprinting come from non-human sources, such as collagen and gelatin derived from animals. While these materials are biocompatible, they have limitations when it comes to replicating the complex mixture of human tissue. For instance, the extracellular matrix (ECM), glycosaminoglycans, and polysaccharides found in human tissue are difficult to accurately replicate using animal-derived bioinks.

One popular gelatinous protein ECM material used in bioprinting is Matrigel, derived from mouse tumor models. However, HU3DINKS argues that Matrigel’s ethically questionable origins, over-expression of growth factors, and batch-to-batch variability make it unsuitable for clinical applications. Therefore, there is a pressing need for alternatives that not only address ethical concerns but also accurately emulate human tissue processes and conditions.

While synthetic polymers have been explored as alternatives, they present a simplified version of the complexity found in the human body. This gap between laboratory tests using synthetic polymers and animal models has prompted HU3DINKS to focus on creating next-generation human tissue-based bioinks derived from the human placenta. The Human Touch (THT) Biomaterials and other humane products will provide the basis for these new bioinks in a cruelty-free manner.

According to HU3DINKS, using human-derived bioinks in 3D printing has vast potential advantages. The consortium plans to utilize commercially available human tissue-derived materials to create bioinks suitable for various printing technologies, including extrusion and light-based processes. These materials can be sourced from biobanks, tissue donations, cell culture laboratories, umbilical cord blood banks, companies specializing in human tissue products, and collaborative hospitals and clinics.

The use of human tissue-based bioinks is gaining traction in the bioprinting field. Notable advancements include bioinks derived from decellularized extracellular matrices of human tissues, which provide a more authentic cellular environment. Human-derived gelatin, platelet lysate, and blood plasma have also emerged as promising materials. Alginate and collagen, although not intrinsically human-derived, can be combined with human cells to produce bioinks that harness human cellular functionality.

Several companies, including Cellink, RegenHU, Aspect Biosystems, Tissue Labs, and Allevi, are actively developing human tissue-based bioinks. These companies, in collaboration with academic labs, seek to innovate and commercialize bioinks that integrate human cells for therapeutic and research applications.

Collaboration is key to the consortium’s success. HU3DINKS partners with renowned biomedicine firms and institutes, including BIO INX, MorphoMed, UpNano, and the Ludwig Boltzmann Institute for Traumatology (LBI Trauma). Each partner brings unique expertise to the table, contributing to the goal of refining commercially available human tissue-derived materials into bioinks that can be seamlessly printed.

Beyond technical innovations, HU3DINKS envisions a future where bioprinting, supported by human tissue-based bioinks, plays a crucial role in regenerative medicine, tissue engineering, and personalized healthcare. The consortium aims to pave the way for groundbreaking applications in healthcare.

In summary, HU3DINKS is championing the development of advanced human tissue-based bioinks for 3D bioprinting, aiming to replace synthetic and animal-derived bioinks. The consortium’s collaboration with industry leaders and academic institutions seeks to revolutionize healthcare and advance the field of bioprinting. Through the use of human-derived bioinks, HU3DINKS aims to create a more accurate and ethical approach to bioprinting that holds great promise for the future of healthcare.

Bioprinting technology has the potential to revolutionize the field of animal-free testing. According to BIO INX, while there are still obstacles to overcome in order to convert these applications to clinical reality, bioprinting technology already provides solutions in this field. The use of “human 3D inks” can make a significant difference in making bioprinting truly animal-free.

One of the major benefits of these advancements is the ability to test pharmaceuticals or cosmetics on 3D printed human tissue models. These models offer a more accurate representation of native 3D tissues compared to traditional 2D cell cultures. This means that researchers can obtain more reliable results and make more informed decisions regarding the safety and effectiveness of these products.

To push bioprinting to even greater heights, technologies like 2PP (Two-photon polymerization) are crucial. Markus Lunzer, a materials specialist at UpNano, emphasizes that while the technology has made significant advances in performance, it is currently limited by the absence of high-performing biological materials. This is where the HU3DINKS project comes in.

The HU3DINKS project aims to induce a paradigm shift in the field of bioprinting by mimicking the human cellular environment in terms of both architecture and composition. By utilizing human tissue-based bioinks and moving away from animal-based materials, this project has the potential to revolutionize bioprinting.

Bringing together experts from all over the world, the HU3DINKS project is paving the way for exciting breakthroughs in medicine and beyond. By focusing on developing high-performing biological materials, they are removing a major hurdle in the advancement of bioprinting technology. This could lead to significant advancements in the development of personalized medicine, tissue engineering, and regenerative medicine.

To stay informed about the latest news and developments in the 3D printing industry, as well as receive information and offers from third party vendors, it is important to stay up-to-date. The bioprinting field is constantly evolving, and remaining knowledgeable about the latest advancements is essential for professionals in the industry.

In conclusion, bioprinting technology has the potential to revolutionize animal-free testing and provide more accurate representations of human tissues. The HU3DINKS project, with its focus on developing high-performing biological materials, is leading the way towards exciting breakthroughs in medicine and other fields. By staying informed and up-to-date, professionals can ensure that they are at the forefront of this revolutionary technology.

Original source


Share this story

Leave a Reply

Your email address will not be published. Required fields are marked *